PERRIGO Co plc (PRGO) director Geoffrey M. Parker reported an automatic conversion of 1,263 Restricted Stock Units into the same number of ordinary shares on September 11, 2026. At a reported value of $13.66 per share, 607 shares were delivered or withheld to cover the exercise price or tax liability, with the balance retained as ordinary shares. Following these transactions, Parker is reported as holding ordinary shares indirectly through a revocable trust and a Roth IRA.
PERRIGO Co plc (PRGO) director Bradley A. Alford reported equity award and related share transactions dated September 11, 2026. He exercised 1,263 Restricted Stock Units, receiving the same number of ordinary shares at $13.66 per share, with each unit representing one ordinary share.
Of the shares received, 607 ordinary shares were delivered or withheld for payment of exercise price or tax liability. Alford also received a new grant of 2,059 Restricted Stock Units, each representing a contingent right to one ordinary share, scheduled to vest on September 11, 2027. No Rule 10b5-1 trading plan is reported for these transactions.
PERRIGO Co plc (PRGO) reported that executive vice president and chief business development officer David Ball exercised 7,701 Restricted Stock Units on September 9, 2026, converting them into 7,701 ordinary shares at $14.34 per share. As part of this event, 2,784 ordinary shares were delivered or withheld to pay the exercise price or related tax liability. No Restricted Stock Units remained from this award after the transaction, and no Rule 10b5-1 trading plan is reported.
PERRIGO Co plc (PRGO) received an amended Schedule 13G filing from T. Rowe Price Associates, Inc. reporting a significantly reduced position in its common stock. T. Rowe Price reports beneficial ownership of 231,010 shares, representing 0.1% of the class, with sole voting power over 225,136 shares and sole dispositive power over 231,010 shares.
T. Rowe Price states that it now holds 5% or less of Perrigo’s common stock and expressly denies being the beneficial owner of the reported securities beyond this technical reporting status.
T. Rowe Price Associates, Inc. reports beneficial ownership of 8,700,421 shares of Perrigo Company plc common stock, representing 6.3% of the class as of June 30, 2026. It has sole voting power over 8,666,232 shares and sole dispositive power over 8,700,421 shares, with no shared voting or dispositive power.
The firm states that this report should not be construed as an admission that it is the beneficial owner of these securities and expressly denies such beneficial ownership.
Perrigo Company plc reported second‑quarter 2026 continuing‑operations net sales of $1,022.8 million, down 3.2% year over year, as category softness and lower retail inventories weighed on Core Self Care and Specialty Care. Reported diluted EPS was $0.63 versus $0.00, aided by the gain on the Dermacosmetics divestiture.
All In adjusted diluted EPS was $0.50, down from $0.57, with adjusted gross margin contracting to 35.6% and adjusted operating margin to 12.2%. Core net sales were $907 million, down 3.1%, while Infant Formula net sales rose 23.1% to $100.9 million with improved profitability.
The company generated $83 million of net cash from operating activities in the quarter ended June 27, 2026, held $400 million of cash and cash equivalents and had total debt of $3.3 billion. Approximately $359 million of Dermacosmetics proceeds were applied to debt reduction, and management reaffirmed 2026 adjusted EPS guidance of $2.00–$2.30 All In and $2.25–$2.55 Core.
BlackRock, Inc. filed an amended Schedule 13G reporting beneficial ownership of 20,988,733 shares of Perrigo Company plc common stock. This represents 15.2% of the class as of the reported date.
BlackRock reports sole voting power over 20,758,891 shares and sole dispositive power over 20,988,733 shares, with no shared voting or dispositive power. The filing notes that certain business units of BlackRock are aggregated for this report, while others are disaggregated under SEC Release No. 34-39538. One such person, iShares Core S&P Small-Cap ETF, is stated to have an interest in more than five percent of Perrigo’s outstanding common stock.
Manzone Albert reported acquisition or exercise transactions in this Form 4 filing.
Perrigo Company plc granted its interim President and CEO, Albert Manzone, 235,627 Restricted Stock Units on July 8, 2026. Each RSU represents a contingent right to receive one ordinary share and will vest upon the earlier of July 8, 2027, the hiring of a permanent CEO, or termination of employment in connection with a change of control under Perrigo's 2026 Long-Term Incentive Plan. Following this award, Manzone directly holds 16,353 ordinary shares.
Amin Ahmed Salman reported acquisition or exercise transactions in this Form 4 filing.
Perrigo Company plc director Ahmed Salman Amin reported an equity compensation award. On July 8, 2026, he received 14,964 Restricted Stock Units, each representing a contingent right to one ordinary share, vesting on July 8, 2027. Following the grant, he holds 14,964 RSUs directly and no non-derivative shares.